[go: up one dir, main page]

HK1247789A1 - 用於治療水腫的組合物和方法 - Google Patents

用於治療水腫的組合物和方法

Info

Publication number
HK1247789A1
HK1247789A1 HK18107279.7A HK18107279A HK1247789A1 HK 1247789 A1 HK1247789 A1 HK 1247789A1 HK 18107279 A HK18107279 A HK 18107279A HK 1247789 A1 HK1247789 A1 HK 1247789A1
Authority
HK
Hong Kong
Prior art keywords
edema
compositions
treatment
methods
Prior art date
Application number
HK18107279.7A
Other languages
English (en)
Inventor
Mehrara Babak
Gardenier Jason
SAVETSKY Ira
ARAS Omer
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of HK1247789A1 publication Critical patent/HK1247789A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK18107279.7A 2015-02-05 2018-06-04 用於治療水腫的組合物和方法 HK1247789A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562112273P 2015-02-05 2015-02-05
PCT/US2016/016680 WO2016127013A1 (en) 2015-02-05 2016-02-05 Compositions and methods for treatment of edema

Publications (1)

Publication Number Publication Date
HK1247789A1 true HK1247789A1 (zh) 2018-10-05

Family

ID=56564721

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18107279.7A HK1247789A1 (zh) 2015-02-05 2018-06-04 用於治療水腫的組合物和方法

Country Status (8)

Country Link
US (4) US10251871B2 (zh)
EP (1) EP3253211A4 (zh)
JP (2) JP6704403B2 (zh)
CN (2) CN114588154A (zh)
AU (2) AU2016215173B2 (zh)
CA (1) CA2975879A1 (zh)
HK (1) HK1247789A1 (zh)
WO (1) WO2016127013A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10251871B2 (en) * 2015-02-05 2019-04-09 Memorial Sloan Kettering Cancer Center Compositions and methods for treatment of edema
EP3500308A4 (en) * 2016-08-18 2020-04-22 Memorial Sloan Kettering Cancer Center INHIBITION OF THE SPHINGOSIN-1-PHOSPHATE RECEPTOR FOR TREATING AND PREVENTING LYMPHEDEMES
EP4427815A3 (en) * 2018-09-14 2024-11-06 Puretech Lyt 100, Inc. Deuterium-enriched pirfenidone and methods of use thereof
US20220040138A1 (en) * 2018-11-05 2022-02-10 Apramitha Innovations Private Limited Teriflunomide topical pharmaceutical compositions
WO2021186401A1 (en) * 2020-03-18 2021-09-23 Puretech Lyt 100, Inc. Methods of treating lymphedema with deupirfenidone
CN112642065B (zh) * 2020-12-28 2022-08-02 锐可医疗科技(上海)有限公司 激光治疗仪及存储介质
WO2024059336A1 (en) * 2022-09-18 2024-03-21 Memorial Sloan Kettering Cancer Center Inhibition of protease-activated receptor 2 (par2) pathway for treatment and prevention of lymphedema

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005011669A1 (ja) * 2003-08-05 2005-02-10 Dainippon Sumitomo Pharma Co., Ltd. 経皮投与用医薬組成物
US20050158371A1 (en) * 2002-02-12 2005-07-21 Sumitomo Pharmaceuticals Co., Ltd. Novel external agent
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
CN101460060A (zh) * 2006-03-01 2009-06-17 特莱斯特拉塔公司 局部治疗焦油响应性皮肤病用的组合物和方法
BRPI0709016A2 (pt) * 2006-03-23 2011-06-21 Macusight Inc formulações e métodos para doenças ou condições relacionadas com a permeabilidade vascular
CN101484167B (zh) * 2006-06-15 2012-07-04 上海睿星基因技术有限公司 吡啶酮类衍生物预防和治疗放射性肺损伤的用途
WO2008116135A2 (en) * 2007-03-22 2008-09-25 Cytotech Labs, Llc Topical formulations having enhanced bioavailability
CA2741954A1 (en) * 2008-10-29 2010-05-06 Pacific Therapeutics Ltd. Composition and method for treating fibrosis
US7635707B1 (en) 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
TW201032796A (en) * 2009-02-04 2010-09-16 Bipar Sciences Inc Treatment of lung cancer with a PARP inhibitor in combination with a growth factor inhibitor
DE102010015143A1 (de) * 2010-04-16 2011-10-20 Cts Chemical Industries Ltd. Stabile flüssige ölige gebrauchsfertige Formulierungen, Herstellung davon und Verwendung davon
US10251871B2 (en) * 2015-02-05 2019-04-09 Memorial Sloan Kettering Cancer Center Compositions and methods for treatment of edema
US10292961B2 (en) * 2015-07-15 2019-05-21 Hangzhou Dac Biotech Co., Ltd. Disulfur bridge linkers for conjugation of a cell-binding molecule

Also Published As

Publication number Publication date
US12144805B2 (en) 2024-11-19
EP3253211A1 (en) 2017-12-13
CN107427007B (zh) 2022-02-11
US20200016137A1 (en) 2020-01-16
US20210069164A1 (en) 2021-03-11
US10874651B2 (en) 2020-12-29
AU2016215173A1 (en) 2017-08-24
JP2020114830A (ja) 2020-07-30
JP6926263B2 (ja) 2021-08-25
EP3253211A4 (en) 2018-10-31
AU2016215173B2 (en) 2019-11-21
CN107427007A (zh) 2017-12-01
US20230241043A1 (en) 2023-08-03
US10251871B2 (en) 2019-04-09
AU2020201161B2 (en) 2021-07-15
JP6704403B2 (ja) 2020-06-03
CA2975879A1 (en) 2016-08-11
WO2016127013A1 (en) 2016-08-11
AU2020201161A1 (en) 2020-03-05
JP2018504436A (ja) 2018-02-15
US11583523B2 (en) 2023-02-21
CN114588154A (zh) 2022-06-07
US20180028514A1 (en) 2018-02-01

Similar Documents

Publication Publication Date Title
IL258955A (en) Preparations and methods for the treatment of cancer
IL253803B (en) A preparation for the treatment of hypothyroidism
IL247942A0 (en) Compositions and methods for drops in macular edema as a result of diabetes
HK1247789A1 (zh) 用於治療水腫的組合物和方法
RS61703B1 (sr) Kompozicije i postupci za lečenje i prevenciju zapaljenja
HK1244711A1 (zh) Hmgb1介導的炎症的治療
SG11201702554QA (en) Compositions and methods for the treatment of multiple sclerosis
HK1255221A1 (zh) 使用卡多曲組合物進行治療的方法
HK1258502A1 (zh) 用於治療高胱氨酸尿症的組合物和方法
IL259710A (en) Preparations and methods for the treatment of Davidson's disease (microvillus inclusion disease) and related diseases
HK1250145A1 (zh) 治療多發性骨髓瘤的組合物和方法
HK1255695A1 (zh) 用於治療眼瞼下垂的組合物和方法
GB201511799D0 (en) Composition and methods of treatment
HK1243937A1 (zh) 治療疾病的方法
GB201621737D0 (en) Compositions and methods of treatment
IL257407A (en) Compositions and methods for treating wounds
IL252707B (en) Compositions and methods for treating diseases
DK3313207T3 (en) Compositions and methods for the treatment of malnutrition
GB201605127D0 (en) Composition and methods of treatment
HK1252385A1 (zh) 錫生藤提取物治療登革熱的用途
HK1243343A1 (zh) 含脫輔基水母發光蛋白的組合物及其用於治療神經元炎症的方法
GB201512139D0 (en) Methods of treatment
SG10201913141UA (en) Treatment of alphavirus-induced inflammation
GB201521083D0 (en) Compositions for treatment and methods thereof
AU2015903210A0 (en) Compositions and methods of treatment